Since treatment with AVL-292 led to an increase in E-Cadherin expression and, at the same time, to a reduction in Slug protein levels, BTK inhibition may represent a powerful tool to interfere with the EMT and metastatic phenotype of HNSCC, thus improving the OS and DFS of head and neck cancer patients. This evidence concerns the gene CDH1 and head and neck squamous cell carcinoma.